Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Phase 2

Terminated

Conditions: Acral Lentiginous Melanoma
Mucosal Melanoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2016-12-01

Last Posted Date: 2024-04-04

Lead Sponsor: Georgetown University

Target Recruit Count: 14

Registration Number: NCT02978443

Locations: 🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cacner Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

and more 2 locations

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

Phase 2

Withdrawn

Conditions: Metastatic Pancreatic Cancer

Interventions: Other: Molecularly Tailored Second Line Therapy
Drug: Standard of Care Second Line Therapy

First Posted Date: 2016-11-18

Last Posted Date: 2018-09-11

Lead Sponsor: Georgetown University

Registration Number: NCT02967770

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

The Genetic Education for Men Trial: Web-Based Education vs. Standard Care

Not Applicable

Completed

Conditions: BRCA2 Mutation
BRCA1 Mutation
Prostate Carcinoma
Breast Neoplasm
Pancreatic Cancer

Interventions: Behavioral: Web-based Counseling
Behavioral: Standard Care

First Posted Date: 2016-11-08

Last Posted Date: 2023-09-13

Lead Sponsor: Georgetown University

Target Recruit Count: 63

Registration Number: NCT02957981

Locations: 🇺🇸
Georgetown University Medical Center/Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Phase 1

Active, not recruiting

Conditions: Refractory Follicular Lymphoma
Relapsed Follicular Lymphoma

Interventions: Drug: Ibrutinib
Drug: Venetoclax

First Posted Date: 2016-11-06

Last Posted Date: 2024-05-21

Lead Sponsor: Georgetown University

Target Recruit Count: 24

Registration Number: NCT02956382

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Envarsus XR in African American Renal Transplant Recipients

Not Applicable

Terminated

Conditions: Renal Transplant Recipients

Interventions: Drug: ENVARSUS®

First Posted Date: 2016-11-04

Last Posted Date: 2020-03-24

Lead Sponsor: Georgetown University

Target Recruit Count: 18

Registration Number: NCT02956005

Locations: 🇺🇸
Medstar Georgetown Transplant Institute, Washington, District of Columbia, United States

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

Phase 2

Conditions: Parkinson Disease
Parkinsons Disease With Dementia

Interventions: Drug: Nilotinib 300mg oral capsule [Tasigna]
Drug: Placebo Oral Capsule
Drug: Nilotinib 150mg oral capsule [Tasigna]

First Posted Date: 2016-11-04

Last Posted Date: 2019-03-14

Lead Sponsor: Georgetown University

Target Recruit Count: 75

Registration Number: NCT02954978

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

Phase 2

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo Capsule(s) Once a Day by Mouth
Drug: Nilotinib Capsule(s) Once a Day by Mouth

First Posted Date: 2016-10-28

Last Posted Date: 2019-03-13

Lead Sponsor: Georgetown University

Target Recruit Count: 42

Registration Number: NCT02947893

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

Use of Regional Anesthesia in Hip Arthroscopy

Phase 4

Conditions: Hip Injuries

Interventions: Other: Normal Saline Sham Injection
Drug: Ropivacaine
Procedure: General Anesthesia

First Posted Date: 2016-08-02

Last Posted Date: 2018-02-19

Lead Sponsor: Georgetown University

Target Recruit Count: 70

Registration Number: NCT02851888

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

Effectiveness and Efficacy of Dynamic Optimal Timing, a Smart Phone App for Avoiding Pregnancy: an Observational Study

Completed

Conditions: Desire to Avoid Pregnancy

Interventions: Behavioral: Women using Dot to avoid pregnancy

First Posted Date: 2016-07-14

Last Posted Date: 2020-02-17

Lead Sponsor: Georgetown University

Target Recruit Count: 718

Registration Number: NCT02833922

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

Phase 2

Completed

Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer

Interventions: Drug: Palbociclib + Letrozole or Fulvestrant

First Posted Date: 2016-02-26

Last Posted Date: 2021-09-28

Lead Sponsor: Georgetown University

Target Recruit Count: 35

Registration Number: NCT02692755

Locations: 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
MedStar Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy